Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Intensification for IDH Wildtype Lower Grade Glioma
NCT04623931Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in glioma, glioblastoma (GBM), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2020; status: recruiting.
02
Drugs
temozolomide
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT04623931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623931.